Índice Bovespa

US Dollar vs BRL

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

EWTX Edgewise Therapeutics Inc

32,20

0,12 (0,37%)

27 Nov 2024 - Fechado

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/20/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Alan J Russell

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Edgewise Therapeutics (NASDAQ:EWTX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024

Click aqui para mais gráficos Edgewise Therapeutics.

Edgewise Therapeutics (NASDAQ:EWTX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024

Click aqui para mais gráficos Edgewise Therapeutics.

Notícias Edgewise Therapeutics Inc

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
Terça, 26 de Novembro de 2024 (2 dias atrás) • Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans
Quinta, 7 de Novembro de 2024 (3 semanas atrás) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Quinta, 7 de Novembro de 2024 (3 semanas atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Quinta, 7 de Novembro de 2024 (3 semanas atrás) • Edgar (US Regulatory)

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Quinta, 7 de Novembro de 2024 (3 semanas atrás) • Business Wire

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
Terça, 1 de Outubro de 2024 (2 meses atrás) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Terça, 24 de Setembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Terça, 24 de Setembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Sexta, 20 de Setembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Sexta, 20 de Setembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
Quinta, 19 de Setembro de 2024 (2 meses atrás) • Business Wire

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
Terça, 17 de Setembro de 2024 (2 meses atrás) • Business Wire

Mais Notícias de Edgewise Therapeutics Inc

Índice Bovespa

Grupo Casas Bahia ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições